A phase II study of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer

J. Rubin; A. J. Schutt; M. J. O'Connell; M. A. Gertz; C. G. Moertel

doi:10.1097/00000421-198410000-00025

A phase II study of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer

J. Rubin, A. J. Schutt, M. J. O'Connell, M. A. Gertz, C. G. Moertel

Hematology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

A phase II study of BCNU and PALA was undertaken in advanced large bowel carcinoma. Thirty patients with advanced metastatic colorectal carcinoma were treated with the combination BCNU (200 mg/m²) every 6 weeks, and PALA (5.0 g/m²) every 3 weeks. Fifteen patients had received no prior chemotherapy and 15 had been previously treated with one or more cytotoxic agents. Only one patient met the criteria for a partial response, and this response was of only 3 months' duration. It would seem unlikely that the combination of BCNU and PALA holds the potential of response greater than BCNU alone and that further trials of this treatment regimen for this tumor type seem unwarranted.

Original language	English (US)
Pages (from-to)	523-525
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	7
Issue number	5
DOIs	https://doi.org/10.1097/00000421-198410000-00025
State	Published - 1984

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-198410000-00025

Cite this

Rubin, J., Schutt, A. J., O'Connell, M. J., Gertz, M. A., & Moertel, C. G. (1984). A phase II study of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 7(5), 523-525. https://doi.org/10.1097/00000421-198410000-00025

A phase II study of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer. / Rubin, J.; Schutt, A. J.; O'Connell, M. J. et al.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 7, No. 5, 1984, p. 523-525.

Research output: Contribution to journal › Article › peer-review

Rubin, J, Schutt, AJ, O'Connell, MJ, Gertz, MA & Moertel, CG 1984, 'A phase II study of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 7, no. 5, pp. 523-525. https://doi.org/10.1097/00000421-198410000-00025

@article{d58121a8b69342ad85435c5ace3054bb,

title = "A phase II study of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer",

abstract = "A phase II study of BCNU and PALA was undertaken in advanced large bowel carcinoma. Thirty patients with advanced metastatic colorectal carcinoma were treated with the combination BCNU (200 mg/m2) every 6 weeks, and PALA (5.0 g/m2) every 3 weeks. Fifteen patients had received no prior chemotherapy and 15 had been previously treated with one or more cytotoxic agents. Only one patient met the criteria for a partial response, and this response was of only 3 months' duration. It would seem unlikely that the combination of BCNU and PALA holds the potential of response greater than BCNU alone and that further trials of this treatment regimen for this tumor type seem unwarranted.",

author = "J. Rubin and Schutt, {A. J.} and O'Connell, {M. J.} and Gertz, {M. A.} and Moertel, {C. G.}",

year = "1984",

doi = "10.1097/00000421-198410000-00025",

language = "English (US)",

volume = "7",

pages = "523--525",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - A phase II study of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer

AU - Rubin, J.

AU - Schutt, A. J.

AU - O'Connell, M. J.

AU - Gertz, M. A.

AU - Moertel, C. G.

PY - 1984

Y1 - 1984

N2 - A phase II study of BCNU and PALA was undertaken in advanced large bowel carcinoma. Thirty patients with advanced metastatic colorectal carcinoma were treated with the combination BCNU (200 mg/m2) every 6 weeks, and PALA (5.0 g/m2) every 3 weeks. Fifteen patients had received no prior chemotherapy and 15 had been previously treated with one or more cytotoxic agents. Only one patient met the criteria for a partial response, and this response was of only 3 months' duration. It would seem unlikely that the combination of BCNU and PALA holds the potential of response greater than BCNU alone and that further trials of this treatment regimen for this tumor type seem unwarranted.

AB - A phase II study of BCNU and PALA was undertaken in advanced large bowel carcinoma. Thirty patients with advanced metastatic colorectal carcinoma were treated with the combination BCNU (200 mg/m2) every 6 weeks, and PALA (5.0 g/m2) every 3 weeks. Fifteen patients had received no prior chemotherapy and 15 had been previously treated with one or more cytotoxic agents. Only one patient met the criteria for a partial response, and this response was of only 3 months' duration. It would seem unlikely that the combination of BCNU and PALA holds the potential of response greater than BCNU alone and that further trials of this treatment regimen for this tumor type seem unwarranted.

UR - http://www.scopus.com/inward/record.url?scp=0021685216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021685216&partnerID=8YFLogxK

U2 - 10.1097/00000421-198410000-00025

DO - 10.1097/00000421-198410000-00025

M3 - Article

C2 - 6507373

AN - SCOPUS:0021685216

SN - 0277-3732

VL - 7

SP - 523

EP - 525

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 5

ER -

A phase II study of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this